Arrhythmogenic Right Ventricular Cardiomyopathy: Difference between revisions

no edit summary
No edit summary
No edit summary
Line 58: Line 58:
</gallery>
</gallery>


==Table 1==
{| class="wikitable"
{| class="wikitable"
|+ Table 1. Comparison of Original and Revised Task Force Criteria
|+ Table 1. Comparison of Original and Revised Task Force Criteria
Line 104: Line 105:
** Ratio of RV end-diastolic volume to BSA &ge;100 to &lt;110 mL/m<sup>2</sup> (male) or &ge;90 to &lt;100 mL/m<sup>2</sup> (female)
** Ratio of RV end-diastolic volume to BSA &ge;100 to &lt;110 mL/m<sup>2</sup> (male) or &ge;90 to &lt;100 mL/m<sup>2</sup> (female)
** <em>or</em> RV ejection fraction &gt;40% to &le;45%
** <em>or</em> RV ejection fraction &gt;40% to &le;45%
|-
| colspan="2" | II. Tissue characterization of wall
|-
| colspan="2" | Major
|-
| valign="top" |
* Fibrofatty replacement of myocardium on endomyocardial biopsy
|
* Residual myocytes &lt;60% by morphometric analysis (or &lt;50% if estimated), with fibrous replacement of the RV free wall myocardium in &ge;1 sample, with or without fatty replacement of tissue on endomyocardial biopsy
|-
| colspan="2" | Minor
|-
|
| valign="top" |
* Residual myocytes 60% to 75% by morphometric analysis (or 50% to 65% if estimated), with fibrous replacement of the RV free wall myocardium in &ge;1 sample, with or without fatty replacement of tissue on endomyocardial biopsy
|}
|}